A phase II study of a novel anti-tubulin, E7389, in patients with advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Das, A.
Spira, A.
Iannotti, N.
Savin, M.
Zang, E.
Datta, K.
Shapiro, G.
Patturajan, M.
Silberman, S.
机构：
[1] Eisai Med Res Inc, Ridgefield Pk, NJ USA
[2] Fairfax No Virginia Hematol Oncol, Fairfax, VA USA
[3] Hematol Oncol Associates, Port St Lucie, FL USA
[4] Texas Oncol PA, Dallas, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：390S / 390S
页数：1
相关论文
共 50 条
  • [1] Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC)
    Spira, A. I.
    Iannotti, N. O.
    Savin, M. A.
    Neubauer, M.
    Gabrail, N. Y.
    Yanagihara, R.
    Datta, K. K.
    Zang, E. A.
    Fields, S. Z.
    Das, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] E7389, a novel anti-tubulin, in patients with refractory breast cancer.
    Blum, J.
    Forero, L.
    Heiskala, M. K.
    Meneses, N.
    Chandrawansa, K.
    Fang, F.
    Shapiro, G.
    Fields, S. Z.
    Silberman, S.
    Vahdat, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 41S - 41S
  • [3] E7389, a novel anti-tubulin, is safe and effective in patients with refractory breast cancer
    Silberman, SL
    O'Shaughnessy, J
    Vahdat, L
    Fabian, C
    Forero, L
    Rivera, R
    Chandrawansa, K
    Heiskala, M
    Shapiro, G
    Meneses, N
    Fields, SZ
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S60 - S60
  • [4] A Phase II Study of Eribulin Mesylate (E7389) in Patients With Advanced, Previously Treated Non-Small-Cell Lung Cancer
    Spira, Alexander I.
    Iannotti, Nicholas O.
    Savin, Michael A.
    Neubauer, Marcus
    Gabrail, Nashat Y.
    Yanagihara, Ronald H.
    Zang, Edith A.
    Cole, Patricia E.
    Shuster, Dale
    Das, Asha
    [J]. CLINICAL LUNG CANCER, 2012, 13 (01) : 31 - 38
  • [5] A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial.
    Synold, TW
    Morgan, RJ
    Newman, EM
    Lenz, HJ
    Gandara, DR
    Colevas, AD
    Lewis, MD
    Doroshow, JH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 200S - 200S
  • [6] A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane A California Cancer Consortium Trial
    Gitlitz, Barbara J.
    Tsao-Wei, Denice D.
    Groshen, Susan
    Davies, Angela
    Koczywas, Marianna
    Belani, Chandra P.
    Argiris, Athanassios
    Ramalingam, Suresh
    Vokes, Everett E.
    Edelman, Martin
    Hoffman, Philip
    Ballas, Marc S.
    Liu, Stephen V.
    Gandara, David R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (03) : 574 - 578
  • [7] Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea
    Cho, E. K.
    Kang, J. H.
    Han, J-Y.
    Lee, J. S.
    Kim, D-W.
    Kim, S-W.
    Min, Y. J.
    Lee, K. H.
    Kim, J-H.
    Park, K.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [8] Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer (NSCLC).
    Mauer, AM
    Otterson, G
    Rudin, CM
    Villalona, M
    Ansari, RH
    Szeto, L
    Vokes, EE
    [J]. CLINICAL CANCER RESEARCH, 2000, 6 : 4576S - 4576S
  • [9] Phase II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer (NSCLC).
    Lazaro, M
    Jorge, M
    Castellanos, J
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
  • [10] Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer (NSCLC).
    Miller, AA
    Case, D
    Atkins, J
    Giguere, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 649S - 649S
12345